Endo Pulls Opioid Opana ER From The Market After FDA Request

Endo Pharmaceuticals Inc. has agreed to withdraw their opioid painkiller Opana ER from the market following the Food and Drugs Administration (FDA) request. Though they still believe in their product’s safety, their decision to pull the product was made after careful consideration and coordination with the agency. Voluntary Withdrawal From The Market In a press release, Endo Pharmaceuticals announced that they will be removing Opana ER to combat abuse and misuse of the product. As a result, Endo Pharmaceuticals Inc. is expecting to incur approximately $20 million in pre-tax impairment charge…

Read More